期刊文献+

难治性精神分裂症患者认知功能状况及危险因素的研究 被引量:14

The study of cognitive function impairment and its risk factors of patients with treatment-resistant schizophrenia
原文传递
导出
摘要 目的评估难治性精神分裂症(TRS)患者认知功能的状况及可能的危险因素。方法选取36名难治性精神分裂症患者(难治组)和57名非难治性患者(非难治组)及50名健康人(对照组)入组,采用重复性成套神经心理状态测验(RBANS)评估所有参与者的神经认知功能。采用阳性和阴性症状量表(PANSS)评估患者的精神症状。结果患者组认知功能差于正常组,TRS认知功能差于非TRS患者,差异具有统计学意义(P<0.05)。多元回归分析显示高含量抗胆碱能的抗精神病药物是患者即刻记忆(β=12.242,t=11.271,P=0.000)和延时记忆(β=7.391,t=3.354,P=0.001)损害的独立危险因素,阴性症状是注意功能(β=11.147,t=9.436,P=0.002)损害的独立危险因素。结论 TRS比非TRS患者拥有更严重的认知功能缺陷。抗精神病药物(高含量抗胆碱能活性)和阴性症状是影响TRS患者认知功能的危险因素。 Objective The aim of this study was to evaluate cognitive function impairment and its risk factors of patients with treatment-resistant schizophrenia(TRS). Method 36 TRS patients and 57 non-TRS and 50 healthy controls subjects were enrolled in the study. Psychiatric symptoms(except for healthy controls)and cognitive functioning were evaluated. Results The schizophrenia patients had a moe severe cognitive impairment than the normal group. And TRS patients were worse than non-TRS patients(P〈0.05). Multiple regression analysis showed that high anticholinergic activity of antipsychotics had debilitating effect on immediate memory(β=12.242,t=11.271,P=0.000)and delayed memory(β=7.391,t=3.354,P=0.001),negative symptoms were independent risk factors for attention(β=11.147,t=9.436,P=0.002). Conclusion Cognitive deficits are more severe in TRS patients than in non-TRS subjects,and antipsychotics that exert high anticholinergic activity as well as negative symptoms were the risk factors.
作者 李广新 余逗逗 马利 乔云飞 肖文焕 LI Guangxin;YU Doudou;MA Li(Wutaishan Hospital of Medical college of Yangzhou University,Yangzhou 225003,China)
出处 《国际精神病学杂志》 2018年第4期629-631,641,共4页 Journal Of International Psychiatry
关键词 精神分裂症 难治性 认知功能 危险因素 Schizophrenia Treatment resistance Cognitive function Risk factor
  • 相关文献

参考文献1

二级参考文献8

  • 1Takase M, Kanahara N, Oda Y, et al. Dopamine supersen- sitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol. 2015 , 29 (4): 383-389. 被引量:1
  • 2Burton CZ, Vella L, Kelsoe JR, et al. Antipsychotic, an- tidepressant, and cognitive-impairment properties of antipsy-chotics: rat profile and implications for behavioral and psycho- logical symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol. 2014, 387 (6): 545-557. 被引量:1
  • 3Zaytseva Y, Chan RC, P6ppel E, et al. Luria revisited: cog- nitive research in schizophrenia, past implications and future challenges. Philos Ethics Humanit Med. 2015, 10 ( 1 ): 4. 被引量:1
  • 4Abi-Dargham A. Schizophrenia: overview and dopamine dys- function. J Clin Psychiatry, 2014, 75 ( 11 ): e31. 被引量:1
  • 5Heckman PR, Blokland A, Ramaekers J, et al. PDE and cognitive processing: Beyond the memory domain.Neuro- biol Learn Mem. 2015, 119: 108-122. 被引量:1
  • 6Thorsen AL, Johansson K, Loberg EM. Neurobiologyof cog- nitive remediation therapy for schizophrenia: a systematic re- view. Front Psychiatry, 2014, 5: 103. 被引量:1
  • 7谭西英,甘景梨,高存友,段惠峰.精神分裂症患者的认知功能损害[J].国际精神病学杂志,2011,38(1):33-36. 被引量:61
  • 8方政华,周剑,左静,曾宪祥.利培酮与阿立派唑治疗女性精神分裂症对照研究[J].湖南师范大学学报(医学版),2014,11(1):79-81. 被引量:55

共引文献21

同被引文献148

引证文献14

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部